“Phal-501 can be a great drug that has the potential to change the lives of many patients with severe COPD.”
Welcome to PharmaLundensis!
PharmaLundensis develops drugs that bind and excrete heavy metals such as mercury, lead and cadmium from the body. This is expected to bring significant health improvements in a number of diseases.
Latest in News
PharmaLundensis Business Plan Spring 2026.
PharmaLundensis is now looking for contacts with international investors to secure MUSD 6 to finance GMP production of Phal-501 and Proof-of-concept clinical studies on patients with COPD and chronic fatigue syndorme. An updated Business plan is presented which will be used in these contacts.
* Positive results in animal toxicology tests with Phal-501
* Publication of patent application for Phal-501
* Positive patent notice for Phal-501
Phal-501 binds methylmercury very effectively
Methylmercury fits like a glove on the Phal-501, which is visible both from above and from the
side. Sulfur has a very strong tendency to bind to mercury. Five sulfur atoms surround the
mercury atom, creating an extremely strong bond.
Function and benefits of Phal-501
Phal-501 provides a strong and long-lasting binding of mercury and probably also lead and cadmium. Furthermore, Phal-501 is expected to have very small side effects, if any, as the substance never enters the bloodstream. After swallowing, Phal-501 binds heavy metals in the intestine and then goes directly into the stool. This allows the body’s heavy metals to be “leached out” and rendered harmless.
News
PharmaLundensis new Business Plan
Publication of rights issue material